ArticleInternational journal of clinical and experimental medicine2015
Association between XRCC1 Arg399Gln polymorphism and glioma risk in a Chinese population: a case-control study.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 7 citations in OpenAlex.
- Review
- EFEMP1 rs3791679 polymorphism was associated with susceptibility to glioma.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimIn China, the incidence rates of glioma tend to be increased, however, the genetic contribution to its etiology is not well-understood. The aim of this study is to evaluate the association of XRCC1 Arg399Gln polymorphism with glioma risk in a Chinese population. MATERIALS AND
methodsWe conducted a case-control study on 387 patients with glioma and 400 cancer-free controls between 2004 and 2014. Peripheral blood samples of both groups were processed for DNA extraction and genotyping of the XRCC1 Arg399Gln polymorphism using PCR-RFLP. Comparison of the distribution of Arg399Gln genotypes in the study groups was performed by means of 2-sided contingency tables using the χ(2) test. Hazard ratios (HRs) were estimated by Cox proportional hazard regression model.
resultsWhen the AA genotype was used as the reference group, the GG genotype was associated with significantly increased risk for glioma (adjusted OR = 3.18, 95% CI = 1.38-3.88; P = 0.017). Under the dominant model of inheritance, the AG + GG genotype was associated with significantly increased risk for glioma (adjusted OR =2.33, 95% CI = 1.12-5.81; P = 0.023). When the A allele was used as the reference group, the G allele was associated with increased glioma risk (adjusted OR, 2.44, 95% CI, 1.76-4.18; P = 0.003).
conclusionOur data suggests that XRCC1 Arg399Gln polymorphism contribute to increased risk of glioma, which may be susceptibility biomarkers for glioma.
Indexed as
Identifiers
26309694PMC4537963W1199905679What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.